Healthcare Industry News: dementia
News Release - June 20, 2006
U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's DiseaseNymox Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease
HASBROUCK HEIGHTS, N.J.--(HSMN NewsFeed)--June 20, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Three newly published studies from Harvard University, Massachusetts Institute of Technology, University of Jena, New York University and Georgetown University Medical Center have provided data on the mechanisms whereby the statin drugs are believed to produce these beneficial effects on the brain.
Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S.
In the Harvard-MIT Study (J.Neurochem. 2006; 97:716-723) the data showed that statin treatment increased neurite growth in brain cells by inhibiting certain specific signaling proteins (geranylgeranylated proteins). The study from the University of Jena (Restor. Neurol. Neurosci 2006; 24:79-95) summarized a wide body of information on the neuroprotective effects of statin drugs, including multiple effects on endothelial function, cell proliferation, inflammatory response, immunological reactions, platelet function, and lipid oxidation. The paper from NYU and Georgetown University (Neuromolecular Med. 2006; 8:319-328) reported on the finding that statins cause brain cholesterol to translocate within the plasma membrane, but do not lower brain cholesterol, suggesting that statin effects on cholesterol distribution produces the beneficial effects of the drugs on the brain.
The potential for statin drugs to treat or reduce the risk of Alzheimer's disease (AD) has also been bolstered by several other recently published studies and reviews in leading medical and scientific journals. One study followed 3,334 people over the age of 65 for an average of seven years and found that regular statin use was associated with a rate of deterioration less than half of that of untreated patients (Neurology 2005; 65:1388-1394). A second three year study of 342 AD patients found evidence that statins slowed the progression of AD (J. Neurol. Neurosurg. Psychiatry 2005; 76:1624-1629). Recent expert articles reviewing the clinical and scientific evidence in the field have also highlighted the potential of statin drugs for the treatment or prevention of AD: The American Journal of Medicine 2005; 118: 48S-53S; The Lancet Neurology 2005; 4:841-852; Current Opinions in Lipidology 2005;16: 619-623; The Lancet Neurology 2005; 4: 521-2.
The potential use of statins to treat Alzheimer's disease (AD) has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as Arch Neurol (2005; 62:1047-51); Neurology (2005; 64:1531-8); Arch Neurol (2005; 62:753-7); J Neurol Sci (2005; 229-230:147-50); Arch Gen Psychiatry (2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19); J Biol Chem (2005; M505268200); PLoS Med (2005; 2:e18); J Neurosci (2005; 25:299-307)).
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
Source: Nymox Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.